Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Expression profiling of primary leukemia initiating cell-enriched population induced by AML1-ETO9a

ABSTRACT: Combined gene expression and DNA occupancy profiling identifies JAK/STAT signaling as a valid therapeutic target of t(8;21) AML t(8;21) is commonly associated with acute myeloid leukemia (AML). The resulting AML1-ETO fusion proteins are involved in the pathogenesis of AML. To identify novel molecular and therapeutic targets, we performed combined gene expression and promoter occupancy profiling using a primary leukemia initiating cell-enriched population induced by AML1-ETO9a (AE9a). CD45, a negative regulator of cytokine/growth factor receptor and JAK/STAT signaling, is greatly downregulated; furthermore JAK1 and JAK2 are upregulated in these leukemia cells. Consequently, JAK/STAT signaling is enhanced in the AE9a leukemia cells. Importantly, AE9a leukemia cells are highly susceptible to perturbation of JAK/STAT signaling, and a JAK2-selective inhibitor, TG101209, effectively targets these leukemia cells in vivo, suggesting the potential efficacy of JAK2 inhibitors in treating t(8;21) AML. Wild-type or AE9a leukemic samples in triplicate.

ORGANISM(S): Mus musculus

SUBMITTER: Dong-Er Zhang 

PROVIDER: E-GEOD-15195 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Json Xml
altmetric image

Publications

Chromosome translocation 8q22;21q22 [t(8;21)] is commonly associated with acute myeloid leukemia (AML), and the resulting AML1-ETO fusion proteins are involved in the pathogenesis of AML. To identify novel molecular and therapeutic targets, we performed combined gene expression microarray and promoter occupancy (ChIP-chip) profiling using Lin(-)/Sca1(-)/cKit(+) cells, the major leukemia cell population, from an AML mouse model induced by AML1-ETO9a (AE9a). Approximately 30% of the identified com  ...[more]

Similar Datasets

Transcriptomics Expression profiling of primary leukemia initiating cell-enriched population induced by AML1-ETO9a
2012-09-04 | GSE15195 | GEO
Genomics Paired ChIP-Seq studies of Kasumi-1 t(8;21) AML cells
2020-02-14 | GSE131939 | GEO
Genomics Epigenetic silencing of UBXN8 contributes to leukemogenesis of t(8;21) acute myeloid leukemia
2021-07-31 | GSE155466 | GEO
Transcriptomics Acute myeloid leukemia (AML) patient blasts and healthy hematopoietic stem and progenitor cell (HSPC) RNA-sequencing Data
2021-12-31 | GSE149237 | GEO
Methylation profiling Epigenetic minicircuitry of AML1-ETO/THAP10/MIR383 contributes t(8;21) AML leukemogenesis
2017-04-30 | GSE80508 | GEO
Transcriptomics MEIS2 is a novel oncogenic partner in AML1-ETO positive AML [RNA-Seq mouse]
2016-07-04 | E-GEOD-81329 | biostudies-arrayexpress
Transcriptomics Expression data from AML1-ETO9a mouse primary leukemia blast
2017-06-20 | GSE80579 | GEO
Transcriptomics AML1-ETO induced leukemia stem cell self-renewal depends on Plcg1
2022-05-02 | GSE120828 | GEO
Transcriptomics AML1-ETO induced leukemia stem cell self-renewal depends on Plcg1
2019-09-02 | GSE122062 | GEO
Proteomics HDAC3 preferentially binds to RUNX1 in t(8;21) AML cells and collaborates with RUNX1 to repress AML1-ETO-mediated transcriptional activation
2020-02-17 | PXD017230 | Pride